Stryker edged up in extended trading on Tuesday after the medical technology company reported higher-than-expected profit and sales for Q4, and it guided for Q1 earnings in line with the Wall Street view.
EPS rose to $1.78 in the December quarter from $1.56 a year earlier, topping the $1.76 average estimate of analysts surveyed by Capital IQ.
Q4 sales rose to $3.16 billion from $2.71 billion, above the analyst consensus of $3.15 billion.
Moving forward, the company anticipates Q1 adjusted EPS to be in the range of $1.40 to $1.45. Analysts were looking for $1.43. It also expects 2017 organic sales growth to be in the range of 5.5% to 6.5%.